Breaking News Instant updates and real-time market news.

MRK

Merck

$62.86

0.195 (0.31%)

16:06
10/07/16
10/07
16:06
10/07/16
16:06

Merck Animal Health receives USDA approval of canine flu bivalent vaccine

Merck Animal Health announced that the U.S. Department of Agriculture has approved a license for Nobivac Canine Flu Bivalent vaccine - the first vaccine to aid in the control of disease associated with both canine influenza virus H3N2 and canine influenza virus H3N8. CIV H3N2 was identified last year in the United States following multiple outbreaks throughout the country. "Merck Animal Health has a rich history of vaccine development supported by a wealth of expertise, as well as a deep commitment to bringing innovative products to market that truly impact the health and well-being of animals," said KJ Varma, BVSc, Ph.D., senior vice president, R&D, Merck Animal Health. "Our new bivalent canine influenza vaccine will simplify protection against this disease and is a tremendous example of our ongoing pursuit of the science of healthier animals and our dedication to providing veterinarians with new medicines and vaccines to advance optimal pet care."

  • 07

    Oct

  • 25

    Oct

  • 06

    Nov

MRK Merck
$62.86

0.195 (0.31%)

09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.

TODAY'S FREE FLY STORIES

SNAP

Snap

$22.01

0.43 (1.99%)

06:15
04/28/17
04/28
06:15
04/28/17
06:15
Initiation
Snap initiated  »

Snap initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

IBB

iShares Nasdaq Biotechnology Index

$296.52

0.12 (0.04%)

06:15
04/28/17
04/28
06:15
04/28/17
06:15
Technical Analysis
iShares Nasdaq Biotechnology Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LABD

Daily S&P Biotech Bear 3x Shares

$9.55

-0.27 (-2.75%)

06:14
04/28/17
04/28
06:14
04/28/17
06:14
Technical Analysis
Daily S&P Biotech Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWH

MSCI Hong Kong Index

$22.89

0.17 (0.75%)

06:14
04/28/17
04/28
06:14
04/28/17
06:14
Technical Analysis
MSCI Hong Kong Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOGL

Alphabet Class A

$891.44

2.3 (0.26%)

, GOOG

Alphabet

$874.25

2.52 (0.29%)

06:14
04/28/17
04/28
06:14
04/28/17
06:14
Recommendations
Alphabet Class A, Alphabet analyst commentary  »

Alphabet price target…

GOOGL

Alphabet Class A

$891.44

2.3 (0.26%)

GOOG

Alphabet

$874.25

2.52 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 16

    May

  • 22

    May

EWG

iShares MSCI Germany

$29.67

-0.06 (-0.20%)

06:14
04/28/17
04/28
06:14
04/28/17
06:14
Technical Analysis
iShares MSCI Germany: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IJR

iShares Core S&P Small Cap ETF

$70.73

-0.07 (-0.10%)

06:13
04/28/17
04/28
06:13
04/28/17
06:13
Technical Analysis
iShares Core S&P Small Cap ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EEM

MSCI Emerging Markets Index

$40.00

-0.05 (-0.12%)

06:13
04/28/17
04/28
06:13
04/28/17
06:13
Technical Analysis
MSCI Emerging Markets Index: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPI

Group 1 Automotive

$74.91

0.86 (1.16%)

06:12
04/28/17
04/28
06:12
04/28/17
06:12
Earnings
Group 1 Automotive reports Q1 ADJ. EPS $1.53, consensus $1.72 »

Reports Q1 revenue $2.5B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 12

    May

EWW

iShares MSCI Mexico

$51.44

0.45 (0.88%)

06:12
04/28/17
04/28
06:12
04/28/17
06:12
Technical Analysis
iShares MSCI Mexico: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COLM

Columbia Sportswear

$59.77

0.34 (0.57%)

06:12
04/28/17
04/28
06:12
04/28/17
06:12
Downgrade
Columbia Sportswear rating change  »

Columbia Sportswear…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCBFF

Standard Chartered

$9.50

0.11 (1.17%)

, NMR

Nomura

$6.47

0.21 (3.35%)

06:11
04/28/17
04/28
06:11
04/28/17
06:11
Periodicals
Nomura sells Standard Chartered stake valued at almost $500M, Bloomberg says »

Nomura (NMR) is selling a…

SCBFF

Standard Chartered

$9.50

0.11 (1.17%)

NMR

Nomura

$6.47

0.21 (3.35%)

BCS

Barclays

$11.51

0.05 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$918.38

9.09 (1.00%)

06:11
04/28/17
04/28
06:11
04/28/17
06:11
Recommendations
Amazon.com analyst commentary  »

Amazon.com price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

  • 16

    May

  • 23

    May

UUP

PowerShares DB US Dollar Index Up

$25.60

0.04 (0.16%)

06:11
04/28/17
04/28
06:11
04/28/17
06:11
Technical Analysis
PowerShares DB US Dollar Index Up: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HST

Host Hotels

$19.24

-0.03 (-0.16%)

06:11
04/28/17
04/28
06:11
04/28/17
06:11
Hot Stocks
Host Hotels reports Q1 comparable RevPAR on a constant dollar basis up 3.4% »

Comparable RevPAR on a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

UDN

PowerShares DB US Dollar Index Down

$21.10

-0.01 (-0.05%)

06:11
04/28/17
04/28
06:11
04/28/17
06:11
Technical Analysis
PowerShares DB US Dollar Index Down: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBR

KBR

$15.48

-0.02 (-0.13%)

06:10
04/28/17
04/28
06:10
04/28/17
06:10
Earnings
KBR backs FY17 adj. EPS view of $1.10-$1.40, sees results above midpoint »

Consensus $1.27. The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

ATHN

athenahealth

$121.45

1.6 (1.34%)

06:09
04/28/17
04/28
06:09
04/28/17
06:09
Recommendations
athenahealth analyst commentary  »

Piper expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 17

    May

HST

Host Hotels

$19.24

-0.03 (-0.16%)

06:08
04/28/17
04/28
06:08
04/28/17
06:08
Hot Stocks
Breaking Hot Stocks news story on Host Hotels »

Host Hotels sees FY17 …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

WDC

Western Digital

$85.71

1.1 (1.30%)

06:08
04/28/17
04/28
06:08
04/28/17
06:08
Technical Analysis
Western Digital trades sharply higher after earnings beat »

In the pre-market the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPE

Expedia

$136.20

0.45 (0.33%)

06:06
04/28/17
04/28
06:06
04/28/17
06:06
Downgrade
Expedia rating change  »

Expedia downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 16

    May

SBUX

Starbucks

$61.30

-0.26 (-0.42%)

06:06
04/28/17
04/28
06:06
04/28/17
06:06
Recommendations
Starbucks analyst commentary  »

Piper still a buyer of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

CPN

Calpine

$9.59

-0.33 (-3.33%)

06:06
04/28/17
04/28
06:06
04/28/17
06:06
Hot Stocks
Calpine sees FY17 adjusted EBITDA $1.8B-$1.95B »

Sees FY17 growth CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MET

MetLife

$52.14

0.25 (0.48%)

06:06
04/28/17
04/28
06:06
04/28/17
06:06
Hot Stocks
MetLife's Kandarian says to invest $1B in efficiency enhancements for 2016-2019 »

MetLife CEO Steve…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 13

    Jun

DRAD

Digirad Corp

$5.15

-0.05 (-0.96%)

06:06
04/28/17
04/28
06:06
04/28/17
06:06
Earnings
Digirad Corp sees FY17 adjusted EPS 10c-15c, consensus 26c »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 28

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.